Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037431694> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2037431694 abstract "The development of acquired chemoresistance is a persistent clinical problem limiting the successful treatment of malignant cancer. Acquired resistance can arise from chemotherapy-induced mutations and increase tumor cell capacity to either repair or tolerate DNA damage. RNA interference (RNAi) gene silencing is a potential therapeutic strategy for cancer therapy and the depletion of crucial gene products involved in these pathways (e.g. Rev1 and Rev3) by RNAi may restore tumor chemosensitivity to treatment. Herein, we report a nanotherapeutic approach towards utilizing a nanocarrier platform capable of delivering cisplatin and anti-Rev1/3 siRNAs in order to circumvent or reverse acquired resistance through synergistic effects. Nanoparticles (NPs) were prepared by self-assembling technique using synthesized cationic lipid compounds and poly (lactide-co-glycolide)-b-poly (ethylene glycol) (PLGA-PEG). The differentially charged hollow core/shell nanostructure comprises three distinct components: inner aqueous hollow core, a middle positively charged lipid compound/PLGA hydrophobic shell, and a relatively neutral outer PEG layer. Resultant NPs are highly stable in aqueous solutions and entrap siRNA (360-420 pmol siRNA/mg NP) in the aqueous core via electrostatic interactions. The cisplatin prodrug with linear hexyl chains, c, t, c [Pt(NH3)2(O2CCH2CH2CH2CH2CH3)2Cl2], could be efficiently encapsulated within hydrophobic shell of NPs. These NPs undergo controlled release of both anti-Rev1/3 and cisplatin over a period of 1 week. The optimal NPs have been evaluated for their loading efficiency, release kinetics of payloads, biocompatibility, gene silencing efficacy and tumor cell-toxicity activity. The in vitro bioactivity of the siRNA-containing NPs was first evaluated in Dual-Luc HeLa cells using anti-firefly luciferase siRNA as a reporter gene. Up to 98% silencing efficacy could be achieved with a siRNA dose (2.5 nM), a result which is markedly better than the commercially available Lipo2000-siRNA complex. The NPs encapsulated with anti-Rev1/3 siRNAs could also enable significant Rev1/3 gene silencing in various human cancer cell lines including MCF-7, MBD-MB-231 and LNCaP. RT-PCR results showed that anti Rev1/3 siRNA-containing NPs with a siRNA dose (5 nM) exhibited sustained significant suppression of both genes (up to 90%) for up to 3 days. More importantly, when MCF-7 cells were treated with NPs containing anti Rev 1/3 siRNA and cisplatin, there was a significant enhancement in cell apoptosis as compared to populations without siRNA treatment at equivalent cisplatin dosages. Synergistic efficacy of NP[Rev1/3 siRNA+Pt] is under investigation in tumor-bearing mice. Our results provide a promising strategy toward effective sensitizing resistant cancer to chemotherapy by co-delivering gene-specific siRNAs and anti-cancer drugs. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1955. doi:1538-7445.AM2012-1955" @default.
- W2037431694 created "2016-06-24" @default.
- W2037431694 creator A5001574530 @default.
- W2037431694 creator A5042597057 @default.
- W2037431694 creator A5053752264 @default.
- W2037431694 creator A5055667105 @default.
- W2037431694 creator A5059888725 @default.
- W2037431694 creator A5090953868 @default.
- W2037431694 creator A5091627358 @default.
- W2037431694 date "2012-04-15" @default.
- W2037431694 modified "2023-09-23" @default.
- W2037431694 title "Abstract 1955: Simultaneous delivery of siRNA and cisplatin by polymer-lipid hybrid nanoparticles sensitizes resistant cancer to chemotherapy" @default.
- W2037431694 doi "https://doi.org/10.1158/1538-7445.am2012-1955" @default.
- W2037431694 hasPublicationYear "2012" @default.
- W2037431694 type Work @default.
- W2037431694 sameAs 2037431694 @default.
- W2037431694 citedByCount "0" @default.
- W2037431694 crossrefType "proceedings-article" @default.
- W2037431694 hasAuthorship W2037431694A5001574530 @default.
- W2037431694 hasAuthorship W2037431694A5042597057 @default.
- W2037431694 hasAuthorship W2037431694A5053752264 @default.
- W2037431694 hasAuthorship W2037431694A5055667105 @default.
- W2037431694 hasAuthorship W2037431694A5059888725 @default.
- W2037431694 hasAuthorship W2037431694A5090953868 @default.
- W2037431694 hasAuthorship W2037431694A5091627358 @default.
- W2037431694 hasConcept C104317684 @default.
- W2037431694 hasConcept C109316439 @default.
- W2037431694 hasConcept C119056186 @default.
- W2037431694 hasConcept C12554922 @default.
- W2037431694 hasConcept C166703698 @default.
- W2037431694 hasConcept C178790620 @default.
- W2037431694 hasConcept C18150654 @default.
- W2037431694 hasConcept C185592680 @default.
- W2037431694 hasConcept C202751555 @default.
- W2037431694 hasConcept C22615655 @default.
- W2037431694 hasConcept C2776694085 @default.
- W2037431694 hasConcept C2777230088 @default.
- W2037431694 hasConcept C2777516009 @default.
- W2037431694 hasConcept C2778239845 @default.
- W2037431694 hasConcept C2779820397 @default.
- W2037431694 hasConcept C2780165375 @default.
- W2037431694 hasConcept C502942594 @default.
- W2037431694 hasConcept C54009773 @default.
- W2037431694 hasConcept C54355233 @default.
- W2037431694 hasConcept C55493867 @default.
- W2037431694 hasConcept C67705224 @default.
- W2037431694 hasConcept C86803240 @default.
- W2037431694 hasConceptScore W2037431694C104317684 @default.
- W2037431694 hasConceptScore W2037431694C109316439 @default.
- W2037431694 hasConceptScore W2037431694C119056186 @default.
- W2037431694 hasConceptScore W2037431694C12554922 @default.
- W2037431694 hasConceptScore W2037431694C166703698 @default.
- W2037431694 hasConceptScore W2037431694C178790620 @default.
- W2037431694 hasConceptScore W2037431694C18150654 @default.
- W2037431694 hasConceptScore W2037431694C185592680 @default.
- W2037431694 hasConceptScore W2037431694C202751555 @default.
- W2037431694 hasConceptScore W2037431694C22615655 @default.
- W2037431694 hasConceptScore W2037431694C2776694085 @default.
- W2037431694 hasConceptScore W2037431694C2777230088 @default.
- W2037431694 hasConceptScore W2037431694C2777516009 @default.
- W2037431694 hasConceptScore W2037431694C2778239845 @default.
- W2037431694 hasConceptScore W2037431694C2779820397 @default.
- W2037431694 hasConceptScore W2037431694C2780165375 @default.
- W2037431694 hasConceptScore W2037431694C502942594 @default.
- W2037431694 hasConceptScore W2037431694C54009773 @default.
- W2037431694 hasConceptScore W2037431694C54355233 @default.
- W2037431694 hasConceptScore W2037431694C55493867 @default.
- W2037431694 hasConceptScore W2037431694C67705224 @default.
- W2037431694 hasConceptScore W2037431694C86803240 @default.
- W2037431694 hasLocation W20374316941 @default.
- W2037431694 hasOpenAccess W2037431694 @default.
- W2037431694 hasPrimaryLocation W20374316941 @default.
- W2037431694 hasRelatedWork W1973838111 @default.
- W2037431694 hasRelatedWork W1977528153 @default.
- W2037431694 hasRelatedWork W2044719325 @default.
- W2037431694 hasRelatedWork W2062029885 @default.
- W2037431694 hasRelatedWork W2134786980 @default.
- W2037431694 hasRelatedWork W2153926033 @default.
- W2037431694 hasRelatedWork W2158787062 @default.
- W2037431694 hasRelatedWork W2222718468 @default.
- W2037431694 hasRelatedWork W2330299153 @default.
- W2037431694 hasRelatedWork W2530101166 @default.
- W2037431694 hasRelatedWork W2767352492 @default.
- W2037431694 hasRelatedWork W2784133301 @default.
- W2037431694 hasRelatedWork W2796548286 @default.
- W2037431694 hasRelatedWork W2957312781 @default.
- W2037431694 hasRelatedWork W2982055989 @default.
- W2037431694 hasRelatedWork W2983556597 @default.
- W2037431694 hasRelatedWork W3098511852 @default.
- W2037431694 hasRelatedWork W3147642880 @default.
- W2037431694 hasRelatedWork W332142748 @default.
- W2037431694 hasRelatedWork W2009451653 @default.
- W2037431694 isParatext "false" @default.
- W2037431694 isRetracted "false" @default.
- W2037431694 magId "2037431694" @default.
- W2037431694 workType "article" @default.